Clinical trials: Plaque
Psoriasis
Mechanism of Action Study for Psoriasis
The objective of this study is to compare the mechanism of action between adalimumab and methotrexate in subjects with psoriasis.
- Trial name
- MOA (NCT00932113)
- Testing
- Methotrexate, Adalimumab (Humira)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Tufts Medical Center
Plaque Psoriasis, Psoriasis
Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis
The purpose of this study is to compare the safety and efficacy of different doses of etanercept for the treatment of moderate to severe psoriasis.
- Trial name
- PRISTINE (NCT00663052)
- Testing
- Etanercept
- Where
- 38 sites in Argentina, Austria and 11 more
- Volunteers
- 273 people
- Sponsor
- Pfizer
Psoriasis Vulgaris, Plaque Psoriasis
Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation
The purpose of this observational study is to document the course of disease and relapse management during treatment with Daivobet® Gel under consideration of patient's individual application habits under daily use conditions.
- Trial name
- NCT01707368
- Testing
- Daivobet® Gel
- Where
- Germany
- Volunteers
- 561 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptimal response may benefit from…
- Trial name
- NCT04102007
- Testing
- Risankizumab
- Where
- 57 sites in United States, Australia and 6 more
- Volunteers
- 244 people
- Sponsor
- AbbVie
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea
- Trial name
- POETYK-PSO-3 (NCT04167462)
- Testing
- BMS-986165
- Where
- 34 sites in China, South Korea and 1 more
- Volunteers
- 220 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis, Immunomodulation
Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis
This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics.
- Trial name
- NCT01736696
- Testing
- tofacitinib
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Pfizer
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic…
- Trial name
- reSURFACE 1 (NCT01722331)
- Testing
- Tildrakizumab 200 mg, Tildrakizumab 100 mg
- Volunteers
- 772 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.
This study was designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to…
- Trial name
- SIGNATURE (NCT01961609)
- Testing
- Secukinumab (AIN457)
- Where
- 54 sites in Ireland, United Kingdom
- Volunteers
- 235 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of Ustekinumab in the treatment of patients with moderate to severe psoriasis in South Korea and Taiwan.
- Trial name
- NCT00747344
- Testing
- Ustekinumab 45 mg - CP, Ustekinumab 45 mg - after CP
- Where
- 5 sites in South Korea, Taiwan
- Volunteers
- 121 people
- Sponsor
- Centocor, Inc.
Chronic Severe Plaque-type Psoriasis
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis.
- Trial name
- NCT02471144
- Testing
- Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Active Comparator: Etanercept
- Where
- 46 sites in United States, Belgium and 17 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis
A multi-centre, randomised, dose ranging study to evaluate the safety and clinical efficacy of GSK2586184 in patients with chronic plaque psoriasis. There will be 2 study cohorts (Cohorts A and B).
- Trial name
- NCT01782664
- Testing
- 100 mg GSK2586184, 200 mg GSK2586184, 400 mg GSK2586184
- Where
- 15 sites in Germany, United Kingdom
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Psoriasis
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. It is caused by an overactive immune system where the body attacks healthy tissue by mistake.
- Trial name
- IMMprint (NCT04713592)
- Testing
- Risankizumab
- Where
- 55 sites in United States, Canada and 2 more
- Volunteers
- 174 people
- Sponsor
- AbbVie
Gingivitis, Dental Plaque
A Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque Removal
The main goal of this study is to evaluate and compare the efficacy of an on-market dentifrice containing 67 percent (%) sodium bicarbonate and 0.31% sodium fluoride to a reference regular fluoride dentifrice on treating gingival…
- Trial name
- NCT05654662
- Testing
- Corsodyl Original Dentifrice, Colgate Cavity Protection Dentifrice
- Where
- United Kingdom
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- HALEON
Psoriasis
The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis
The purpose of this study is to determine the anti-inflammatory effect of high-dose riboflavin supplementation on chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people.
- Trial name
- NCT02622386
- Testing
- Riboflavin
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Psoriasis
Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis
The primary objectives of this study are to evaluate the safety \& efficacy of consecutive treatments of Clobex® Spray and Silkis® Ointment in the management of plaque psoriasis.
- Trial name
- NCT00658788
- Testing
- clobetasol propionate spray 0.05%, calcitriol ointment
- Where
- 12 sites in United States
- Volunteers
- 305 people
- Sponsor
- Galderma R&D
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- ERASURE (NCT01365455)
- Testing
- secukinumab 150 mg
- Where
- 88 sites in United States, Argentina and 10 more
- Volunteers
- 738 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
This is a phase 2, randomized, placebo-controlled, 2-period study to evaluate the safety, tolerability, and efficacy of belumosudil in adult subjects with moderate to severe chronic plaque psoriasis who are candidates for…
- Trial name
- NCT02852967
- Testing
- Belumosudil
- Where
- 14 sites in United States
- Volunteers
- 110 people
- Sponsor
- Kadmon Corporation, LLC
Atherosclerosis, Cardiovascular Disease
High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
The purpose of this study is to investigate the added benefits of increased high-density lipoprotein (HDL) cholesterol serum levels over and above those achieved by lipid lowering therapy guided by current guidelines, in older…
- Trial name
- NIA-Plaque (NCT00127218)
- Testing
- any statin, niacin
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- Johns Hopkins University
Coronary Artery Disease, Atherosclerosis
Rotational Atherectomy Combined With Cutting Balloon to Optimize Stent Expansion in Calcified Lesions
Rotational atherectomy is an established tool to treat blocked arteries in the heart, in which the blockage is due to significant amounts of calcified material.
- Trial name
- ROTA-CUT (NCT04865588)
- Testing
- rotational atherectomy, cutting balloon, plain old balloon
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Samin Sharma, M.D., F.A.C.C., M.S.C.A.I.
Psoriasis Vulgaris, Psoriasis
Tofacitinib Ointment For Chronic Plaque Psoriasis
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested.
- Trial name
- NCT01831466
- Testing
- tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g
- Where
- 54 sites in United States, Canada and 2 more
- Volunteers
- 476 people
- Sponsor
- Pfizer